




RealRate

PHARMACEUTICAL 2022

Histogen Inc.
Rank 328 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Histogen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Histogen Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Histogen Inc. is the variable Net Income, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is -226%, being 51% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	21,609
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,330
Liabilities, Non-Current	4,617
Other Assets	5,237
Other Compr. Net Income	0
Other Expenses	220
Other Liabilities	112
Other Net Income	448
Property and Equipment	399
Research and Development	8,473
Revenues	1,032
Selling, General and Administrative Expense	7,796

Output Variable	Value in 1000 USD
Assets	27,245
Liabilities	7,059
Expenses	16,489
Stockholders Equity	20,186
Net Income	-15,009
Comprehensive Net Income	-15,009
Economic Capital Ratio	-226%